华润医药控股因境内中票及公司债合规要求披露2026年上半年未经审核财务报表

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited
take no responsibility for the contents of this announcement, make no representation as to
its accuracy or completeness and expressly disclaim any liability whatsoever for any loss
howsoever arising from or in reliance upon the whole or any part of the contents of this
announcement.

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT
UNAUDITED FINANCIAL RESULTS OF
CR PHARMACEUTICAL HOLDINGS
FOR THE SIX MONTHS ENDED 30 JUNE 2026
IN RELATION TO ISSUANCE OF MEDIUM TERM NOTES
AND CORPORATE BONDS
IN THE PRC
Reference is made to: (i) the announcement dated 29 May 2026 in relation to, among others,
the proposed issuance of medium term notes in the PRC by China Resources Pharmaceutical
Holdings Company Limited (華潤醫藥控股有限公司) (“CR Pharmaceutical Holdings”),
a wholly owned subsidiary of the Company; (ii) the announcement dated 22 July 2026 in
relation to, among others, the completion of the issuance of the first tranche of medium term
notes for the year of 2026 in the PRC by CR Pharmaceutical Holdings; (iii) the announcement
dated 29 July 2026 in relation to, among others, the completion of the issuance of the
second tranche of medium term notes for the year of 2026 in the PRC by CR Pharmaceutical
Holdings; and (iv) the announcement dated 16 April 2026 in relation to, among others, the
completion of the issuance of the first tranche of corporate bonds in 2026 in the PRC by CR
Pharmaceutical Holdings (the “Announcements”). Capitalised terms used herein shall have
the same meanings as those defined in the Announcements unless stated otherwise herein.
In accordance with the relevant rules and regulations in the PRC and in connection with its
issuance of medium term notes and corporate bonds in the PRC, CR Pharmaceutical Holdings
has published its unaudited financial statements for the six months ended 30 June 2026 on the
websites of China Money and Shanghai Clearing House in connection with the medium term
notes, and on the website of the Shanghai Stock Exchange in connection with the corporate
bonds.

–1–

The unaudited financial statements of CR Pharmaceutical Holdings for the six months ended
30 June 2026 (the “Unaudited Financial Statements of CR Pharmaceutical Holdings”)
are enclosed to this announcement for the Company’s shareholders’ information only. The
Unaudited Financial Statements of CR Pharmaceutical Holdings were prepared in Chinese and
have been translated for publication in English and Chinese. In the event of any inconsistency
between the two versions, the Chinese version shall prevail. In addition, the Unaudited
Financial Statements of CR Pharmaceutical Holdings have been prepared in accordance with
the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by
the Company’s auditors, and may require adjustments during the course of auditing. Such
financial information is limited to CR Pharmaceutical Holdings only and does not represent or
provide a complete view of the operational or financial status of the Group.
Shareholders and potential investors should exercise caution when dealing in securities
of the Company and should not rely solely on such information.
By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman
PRC, 31 August 2026
As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and
executive Director, Mr. Cheng Jie and Mr. Liu Changan as executive Directors, Mdm. Guo
Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mdm. Zhang Jing and Mdm. Jiao Ruifang as
non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and
Mr. Shi Luwen as independent non-executive Directors.

–2–

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
CONSOLIDATED BALANCE SHEET
JUNE 2026
Unit: RMB
Item
Current assets:
Monetary fund

Closing balance

Held-for-trading financial assets

10,879,098,404.39

Derivative financial assets
Notes receivable
Accounts receivable
Financing receivables
Prepayment
Other receivables
Including: Interest receivable
Dividends receivable
Inventory
Including: Raw materials
Goods in stock
(finished products)
Contract assets
Assets held for sale
Non-current assets due within
one year
Other current assets

Total current assets
Non-current assets:
Other debt investments
Debt investments
Long-term receivables
Other equity instruments
investments
Long-term equity investments
Investment properties
Other non-current financial assets
Fixed assets
Including: Disposal of fixed assets
Right-of-use assets
Construction in progress
Including: Construction materials
Biological assets for production
Oil and gas assets

Opening Balance

Closing balance

374,454,089.28
99,068,638,292.38
13,525,522,072.38
3,961,276,642.20
9,635,870,826.95
132,725.08
0.00
45,080,474,462.02
3,634,045,013.21

Item
Current liabilities:
24,173,133,594.20 Short-term borrowings
Held-for-trading financial
12,069,041,094.95
liabilities
Notes payable and accounts
–
payable
586,483,121.19
Including: Notes payable
92,595,722,664.81
Accounts payable
13,178,431,543.53 Receipts in advance
4,016,056,359.42 Contract liabilities
8,622,449,150.11 Staff remuneration payable
836,001.52
Including: Wages payable
0.00
Benefits payable
43,276,039,279.45 Taxation payable
3,202,249,965.23
Including: Tax payable

37,257,851,681.00

35,292,622,462.01

41,872,924.04
35,325,622.46

55,493,546.50
37,996,383.69

2,483,202,773.94

3,235,028,566.39

2,147,064,651.73

2,301,374,310.71

24,680,256,863.94

–

211,913,057,625.71
(0.00)
83,280,094.96
707,155,910.31

Opening Balance

44,692,759,737.02

40,737,794,364.47

–

–

65,908,865,355.13

64,745,270,978.14

20,297,849,182.80
45,611,016,172.33
355,407,534.46
3,224,567,057.34
3,475,568,745.16
861,876,546.30
–
1,631,661,027.51
1,503,567,571.30

21,745,649,407.90
42,999,621,570.24
93,937,978.20
4,182,764,833.36
4,211,743,649.25
1,080,675,958.90
–
2,015,479,566.00
1,868,335,230.98

Other payables

24,635,830,504.12

21,431,783,225.55

Including: Interest payable
Dividends payable

8,088,805.93
8,116,592,298.36

7,674,319.44
4,732,832,203.56

–

–

–

–

8,374,185,320.59

8,110,938,853.35

491,284,448.09
152,790,129,729.43

640,430,558.82
146,170,144,007.14

6,461,295,929.71
16,724,264,218.64
404,335,926.29

11,149,853,384.60
10,196,868,303.42
408,549,258.29

Insurance contract liabilities

Liabilities held for sale
Non-current liabilities due within
one year
Other current liabilities
204,147,249,614.95
Total current liabilities
Non-current liabilities:
(0.00) Long-term borrowings
79,280,094.96 Bonds payable
831,459,823.02 Long-term payables

10,942,625.57

10,942,625.57

Including: Long-term payables

160,785,920.00

160,785,920.00

6,159,357,322.02

6,041,161,311.87

243,550,006.29

247,763,338.29

368,892,763.15

353,339,799.28

733,554,214.92

744,513,538.04

828,439,946.03
22,293,386,897.16
11,523,424.85
1,157,390,021.26
3,097,613,615.41
208,228.24
24,382,688.45
–

833,242,321.57
22,712,024,741.91
9,711,113.40
1,279,364,857.34
2,587,796,563.58
168,450.73
20,585,150.19
–

Special payables
Long-term employee remuneration
payable
△Deferred revenue
Estimated liabilities
Deferred income tax liabilities
Lease liabilities
Other non-current liabilities
Including: Special reserve
Total non-current liabilities
Total liabilities

798,590,348.64
1,362,459.98
1,795,841,755.54
723,869,951.72
3,814,940.00

781,520,816.97
1,321,000.65
1,892,214,582.04
730,025,422.66
3,814,940.00

27,646,929,745.43
180,437,059,474.86

25,908,681,246.67
172,078,825,253.81

–3–

Item

Closing balance

Intangible assets

13,253,860,993.21

Including: Land use right
Development expenses
Goodwill
Long-term deferred expenses

5,018,407,870.15
2,939,120,770.30
24,354,410,933.42
461,200,577.98

Deferred income tax assets

2,512,484,138.50

Other non-current assets

4,284,042,317.57

Including: Contract assets

Total non-current assets

Total assets

2,211,431.50

82,535,961,615.29

294,449,019,241.00

Opening Balance

Item
Owners’ equity (or shareholders’
13,309,319,592.85
equity):
4,882,090,433.67 Paid-in capital (equity)
2,960,721,894.91 State-owned capital
24,342,133,911.47 Collective capital
473,179,715.38 Legal person capital
Including: State-owned legal
2,347,164,484.40
person capital
Collectively-owned
3,974,805,304.11
legal person capital
2,342,483.75 Individual’s capital
Foreign capital
Capital surplus
Less: Treasury shares
Other comprehensive income
Including: Differences on
translation of foreign currency
Surplus reserves
82,156,522,192.41 Special reserves
Undistributed profits
Total equity attributable to
owners of the parent company
△Minority interests
Total owners’ equity
286,303,771,807.36 Total liabilities and owners’ equity

–4–

Closing balance

Opening Balance

21,007,000,000.00

21,007,000,000.00

185,353,464.71

165,697,373.12

33,388,819.91

46,898,136.52

18,171,619.40

25,606,055.86

972,961,454.68
4,992,022.37
19,188,969,577.01

972,961,454.68
5,027,989.57
18,176,543,251.84

41,392,665,338.68

40,374,128,205.73

72,619,294,427.45
114,011,959,766.13
294,449,019,241.00

73,850,818,347.82
114,224,946,553.55
286,303,771,807.36

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
CONSOLIDATED STATEMENT OF PROFIT OR LOSS
JANUARY TO JUNE 2026
Unit: RMB

Item
I. Operating revenue
Including: Revenue from principal businesses
Revenue from other businesses
II. Operating costs
Including: Costs for principal businesses
Costs for other businesses
Tax and surcharge
Selling expenses
Management expenses
Including: Entertainment expenses
Research and development expenses
Finance costs
Including: Interest expenses
Interest income
Net loss from exchange
(net gain is represented by “–”)
Other revenue
Gain from investment (loss is represented by “–”)
Including: Gains from investment in associates and
joint ventures
Net gains from hedging exposure (loss is
represented by “–”)
Add: Gains from changes in fair values (loss is
represented by “–”)
Impairment losses of assets
Loss on credit impairment
Gains from disposal of assets
III. Operating profits (loss is represented by “–”)
Add: Non-operating income
Including: Gains from exchanging
non-monetary assets
Government subsidies
Less: Non-operating expenses
Including: Loss on exchanging non-monetary
assets

–5–

Accumulated amount
for the year
135,345,023,439.83
134,436,416,385.13
908,607,054.70
112,731,650,116.58
112,340,862,015.89
390,788,100.69
600,880,475.65
10,145,719,012.94
3,237,724,104.94
20,765,044.65
1,112,513,313.85
790,919,399.87
849,077,013.00
146,470,116.34

Accumulated amount
for the corresponding
period of last year
132,788,187,014.49
131,819,175,565.31
969,011,449.18
110,405,051,414.85
109,852,909,737.49
552,141,677.37
579,908,148.25
9,998,189,637.77
3,149,879,296.45
24,416,660.91
970,848,372.56
804,490,493.72
957,146,131.17
205,354,012.40

40,951,803.53
246,532,315.55
170,541,178.03

8,605,216.38
375,616,257.22
82,373,762.10

146,236,168.09

127,376,865.49

–

–

16,460,592.44
128,567,398.52
641,013,734.75
13,222,857.86
6,402,792,826.60
98,750,504.65

61,246,808.99
227,651,013.87
624,663,311.88
13,182,876.27
6,559,925,029.73
113,180,345.42

–
–
55,156,861.42

–
14,833.18
64,875,650.61

–

–

Item
IV. Total profits (total loss is represented by “–”)
Less: Income tax expenses
V. Net profits (net loss is represented by “–”)
Including: Net profits of the absorbed party before
business combination under common
control
Net profits attributable to the owners of the parent
company
*Gains and losses of minority interests
Profit attributable to holders of perpetual capital
instruments
VI. Other comprehensive income, net of tax
  (I) Other comprehensive income that cannot be
reclassified into profit or loss
Changes arising from remeasurement of defined
benefit plan
Other comprehensive income that cannot be
reclassified into profit or loss under the equity
method
Changes in fair value of other equity instrument
investments
(II) Other comprehensive income that may be
reclassified to profit or loss
Other comprehensive income that may be
reclassified to profit or loss under equity method
Changes in fair value of other debt investments
Amount included in other comprehensive income
on reclassification of financial assets
Provision for credit impairment of other debt
investment
Revaluation of fixed assets
Cash flows hedging reserve
Differences arising from translation of foreign
currency
Others
VII. Total comprehensive income
VIII. Earnings per share:
Basic earnings per share
Diluted earnings per share
Add: Undistributed profit at the beginning of the year
Changes in accounting policies
Losses covered by surplus reserve
Other adjustment factors
–6–

Accumulated amount
for the year
6,446,386,469.83
1,270,860,231.83
5,175,526,237.99

Accumulated amount
for the corresponding
period of last year
6,608,229,724.55
1,365,709,737.55
5,242,519,986.99

1,815,408,773.85
3,294,742,464.14

1,760,234,549.32
3,449,760,437.67

65,375,000.00
(83,813,071.95)

32,525,000.00
(4,748,111.08)

(50,505,211.54)

1,779,097.42

2,704.45

–

(50,507,915.99)

1,721,273.79

(0.00)

57,823.63

(33,307,860.40)

(6,527,208.51)

(50,351.81)
264.35

110,918.16
(12,986.68)

–

–

–
–
–

–
–
–

(33,255,068.49)
(2,704.45)
5,091,713,166.05
–
–
–
18,174,155,591.48
–
–
–

(6,625,139.98)
0.00
5,237,771,875.91
–
–
–
14,950,877,474.62
(0.00)
–
0.00

Item
IX. Distributable profit
Less: Appropriation of statutory surplus reserve
Appropriation for staff bonuses and
benefit funds
Appropriation for reserve funds
Appropriation for company development funds
Others
X. Distributable profit attributable to investors
Preference shares dividends payable
Appropriation of discretionary surplus reserve
Ordinary shares dividends payable
Ordinary shares dividends converted to equity
Others
XI. Undistributed profit

–7–

Accumulated amount
for the year
19,989,564,365.34
0.00

Accumulated amount
for the corresponding
period of last year
16,711,112,023.95
(0.01)

–
–
–
–
19,989,564,365.34

–
–
–
–
16,711,112,023.94

–
(800,000,000.00)
–
(594,788.33)
19,188,969,577.01

–
0.00
–
0.00
16,711,112,023.94

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
CONSOLIDATED STATEMENT OF CASH FLOWS
JANUARY TO JUNE 2026
Unit: RMB
Accumulated amount for
the corresponding
period of last year

Accumulated amount
for the year

Item
I. Cash flows from operating activities:
Cash received from the sales of goods and the rendering of
services

138,716,345,824.69

135,507,491,291.93

53,836,762.11

76,320,240.24

7,217,432,178.84

7,347,921,499.59

Sub-total of cash inflows from operating activities

145,987,614,765.64

142,931,733,031.77

Cash paid for goods purchased and services received

115,423,162,404.46

113,538,539,355.47

Cash paid to and for employees

8,485,704,094.36

7,848,085,899.47

Payments of all types of taxes

5,554,564,618.32

5,476,681,095.13

Cash payments relating to other operating activities

15,075,392,607.24

14,493,601,581.10

Sub-total of cash outflows from operating activities

144,538,823,724.38

141,356,907,931.16

Net cash flow from operating activities

1,448,791,041.26

1,574,825,100.61

Cash received from investment recovery

26,769,699,100.39

17,053,655,729.22

Cash received from returns on investments

350,218,602.95

276,697,356.21

Net cash received from disposals of fixed assets, intangible
assets and other long-term assets

318,456,176.62

46,060,223.24

Net cash received from disposals of subsidiaries and other
operating units

–

11,911,840.85

22,366,509.48

240,751,726.94

Sub-total of cash inflows from investing activities

27,460,740,389.44

17,629,076,876.46

Cash paid to acquire fixed assets, intangible assets and other
long-term assets

1,632,714,643.05

1,506,537,871.93

Cash paid for investments

25,972,990,044.25

16,396,527,175.68

Net cash paid for acquisition of subsidiaries and other
operational units

39,993,482.41

5,109,142,594.38

Cash payments relating to other investing activities

343,402,560.36

(479,208.49)

Sub-total of cash outflows from investing activities

27,989,100,730.07

23,011,728,433.50

Net cash flow from investing activities

(528,360,340.63)

(5,382,651,557.04)

Refund of taxes and levies
Cash received relating to other operating activities

II. Cash Flow From Investing Activities:

Cash received relating to other investing activities

–8–

Accumulated amount
for the year

Item

Accumulated amount for
the corresponding
period of last year

III. Cash flow from financing activities:
19,492,000.00

114,593,600.00

Cash received from borrowings

32,342,296,506.12

40,604,790,301.78

Cash received from issuance of bonds

7,699,820,000.00

5,000,000,000.00

Cash payments relating to other financing activities

2,393,370,709.76

3,303,425,997.44

Sub-total of cash inflows from financing activities

42,454,979,215.88

49,022,809,899.22

Cash payments for debts settlement

38,146,011,708.03

38,956,630,236.10

Cash payments for distribution of dividends, profits, or
interest expenses

2,694,062,264.11

2,458,372,059.72

117,623,400.30

3,471,170.03

Cash payments relating to other financing activities

2,727,310,927.13

2,868,039,263.48

Sub-total of cash outflows from financing activities

43,567,384,899.27

44,283,041,559.30

Net cash flow from financing activities

(1,112,405,683.39)

4,739,768,339.93

IV. Effect of foreign exchange rate changes on cash and cash
equivalents

(29,659,022.05)

1,460,601.10

V. Net increase in cash and cash equivalents

(221,634,004.81)

933,402,484.59

15,765,241,201.49

16,323,306,375.52

15,543,607,196.68

17,256,708,860.11

Cash received from capital contribution
Including: Cash received by subsidiaries from investments
of minority shareholders

Including: Dividends and profits paid by subsidiaries to
minority shareholders

Add: Opening balance of cash and cash equivalent
VI. Closing balance of cash and cash equivalents

–9–

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
BALANCE SHEET
JUNE 2026
Unit: RMB
Item
Current assets:
Monetary fund
Held-for-trading financial assets
Derivative financial assets
Notes receivable
Accounts receivable
Financing receivables
Prepayment
Other receivables
Including: Interest receivable
Dividends receivable
Inventory
Including: Raw materials
Goods in stock
(finished products)
Contract assets
Assets held for sale
Non-current assets due within
one year
Other current assets

Total current assets
Non-current assets:
Other debt investments
Debt investments
Long-term receivables
Other equity instruments
investments
Long-term equity investments
Investment properties
Other non-current financial assets
Fixed assets
Including: Disposal of fixed assets
Right-of-use assets
Construction in progress
Including: Construction materials
Biological assets for production
Oil and gas assets

Closing balance

Opening Balance

1,388,465,410.85
1,557,938,847.27
–
–
–
–
2,233,076.30
14,032,381,079.08
–
8,867,748,449.32
–
–
–
–
–
–
2,413,301.74

16,983,431,715.24
–
–
–
–
16,743,443,766.56
–
–
2,817,777.16
–
23,805,956.33
–
–
–
–

Item
Current liabilities:
605,327,754.56 Short-term borrowings
Held-for-trading financial
1,605,145,283.04
liabilities
Notes payable and accounts
–
payable
–
Including: Notes payable
–
Accounts payable
– Receipts in advance
190,584.60 Contract liabilities
12,231,194,371.37 Staff remuneration payable
–
Including: Wages payable
6,572,748,449.32
Benefits payable
– Taxation payable
–
Including: Tax payable
Other payables
–
–
Including: Interest payable
–
Dividends payable
Insurance contract liabilities
–
2,379,335.64 Liabilities held for sale
Non-current liabilities due within
one year
Other current liabilities
14,444,237,329.21
Total current liabilities
Non-current liabilities:
– Long-term borrowings
– Bonds payable
– Long-term payables
Including: Long-term payables
–
16,698,998,641.73
Special payables
Long-term employee remuneration
–
payable
– △Deferred revenue
2,545,046.50 Estimated liabilities
– Deferred income tax liabilities
27,206,807.21 Lease liabilities
260,030.96 Other non-current liabilities
–
Including: Special reserve
–
Total non-current liabilities
–
Total liabilities

– 10 –

Closing balance

Opening Balance

1,006,471,111.11

1,501,386,666.66

–

–

–
–
–
–
–
57,286,224.80
–
–
7,082,927.12
7,082,927.12

–
–
–
–
–
65,267,041.33
–
–
7,768,096.09
7,768,096.09

1,579,112,939.90
–
800,000,000.00

1,151,408,704.22
–
–

–
–

–
–

1,312,034,422.37
–
3,961,987,625.30

2,312,950,189.86
–
5,038,780,698.16

205,125,187.04
3,726,169,611.11
–

222,082,502.61
2,200,000,000.00
–

–
–

–
–

221,450,000.00
–
–
–
17,733,789.53
–

232,660,000.00
–
–
–
21,133,725.58
–

4,170,478,587.68
8,132,466,212.98

2,675,876,228.19
7,714,656,926.35

Item
Intangible assets
Including: Land use right
Development expenses
Goodwill
Long-term deferred expenses
Deferred income tax assets

Closing balance

Opening Balance
–
–
–
–
–

487,111.47

Other non-current assets
Including: Contract assets

Total non-current assets

Total assets

–
–

16,770,554,611.52

33,753,986,326.76

Item
Owners’ equity (or shareholders’
– equity):
– Paid-in capital (equity)
– State-owned capital
– Collective capital
– Legal person capital
Including: State-owned legal
487,111.47
person capital
Collectively- owned
legal person
–
capital
– Individual’s capital
Foreign capital
Capital surplus
Less: Treasury shares
Other comprehensive income
Including: Differences on
translation of foreign
currency
Surplus reserves
16,729,497,637.87 Special reserves
Undistributed profits
Total equity attributable
to owners of the parent
company
△Minority interests
Total owners’ equity
Total liabilities and owners’
31,173,734,967.08
equity

– 11 –

Closing balance

Opening Balance

21,007,000,000.00

21,007,000,000.00

13,253,773.51
–
74,610,416.58

13,253,773.51
–
74,610,416.58

–
1,213,171,274.84
–
3,313,484,648.85

–
1,213,171,274.84
–
1,151,042,575.80

25,621,520,113.78
–
25,621,520,113.78

23,459,078,040.73
–
23,459,078,040.73

33,753,986,326.76

31,173,734,967.08

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
STATEMENT OF PROFIT OR LOSS
JANUARY TO JUNE 2026
Unit: RMB

Item
I. Operating revenue
    Including: Revenue from principal businesses
Revenue from other businesses
II. Operating costs
    Including: Costs for principal businesses
Costs for other businesses
   Tax and surcharge
   Selling expenses
   Management expenses
    Including: Entertainment expenses
    Research and development expenses
   Finance costs
   Including: Interest expenses
Interest income
Net Loss from exchange
(net gain is represented by “–”)
   Other revenue
    Gain from investment (loss is represented by “–”)
     Including: Gains from investment in
   associates and joint ventures
     Net gains from hedging exposure
   (loss is represented by “–”)
    Add: gains from changes in fair values
(loss is represented by “–”)
      Impairment losses of assets
      Loss on credit impairment
      Gains from disposal of assets
III. Operating profits (loss is represented by “–”)
   Add: Non-operating income
      Including: Gains from exchanging
    non-monetary assets
    Government subsidies
   Less: Non-operating expenses
      Including: Loss on exchanging
   non-monetary assets
– 12 –

Accumulated amount
for the year
471,698.11
–
471,698.11
–
–
–
703,149.03
–
88,569,983.21
25,032.20
–
60,062,898.49
60,751,434.10
722,620.46

Accumulated
amount for the
corresponding
period of last year
471,698.11
–
471,698.11
–
–
–
291,648.33
–
62,850,288.09
53,850.30
–
76,518,876.58
89,379,278.85
13,964,556.56

(1,803,348.74)
–
3,094,598,204.60

(730,955.76)
166,065.61
391,330,397.95

44,445,124.83

67,449,931.01

–

–

16,575,594.73
–
–
–
2,962,309,466.71
675,606.34

17,559,802.84
–
32,069,477.09
–
237,797,674.42
20,411,740.24

–
–
543,000.00

–
–
2,950,000.00

–

–

Item
IV. Total profits (total loss is represented by “–”)
    Less: Income tax expenses
V. Net profits (net loss is represented by “–”)
    Including: Net gains of the absorbed party before
business combination under common
control
    Net profits attributable to the owners of the parent
company
    *Gains and losses of minority interests
    Profit attributable to holders of perpetual capital
instruments
VI. Other comprehensive income, net of tax
    (I) Other comprehensive income that cannot be
      reclassified into profit and loss
      Changes arising from remeasurement of
defined benefit plan
       Other comprehensive income that cannot be
reclassified into profit or loss under the
equity method
       Changes in fair value of other equity instrument
investments
    (II) Other comprehensive income that may be
      reclassified to profit or loss
       Other comprehensive income that may be
reclassified to profit or loss under equity
method
       Change in fair value of other debt investments
      Amount included in other comprehensive
income on reclassification of financial
assets
       Provision for credit impairment of other debt
investment
      Revaluation of fixed assets
      Cash flows hedging reserve
      Exchange differences arising from translation
of foreign currency
      Others
VII. Total comprehensive income
VIII. Earnings per share:
    Basic earnings per share
    Diluted earnings per share
    Add: undistributed profit at the beginning of the year
Changes in accounting policies
Losses covered by surplus reserve
Other adjustment factors
– 13 –

Accumulated amount
for the year
2,962,442,073.05
–
2,962,442,073.05

Accumulated
amount for the
corresponding
period of last year
255,259,414.66
(668,644.86)
255,928,059.52

2,962,442,073.05
–

255,928,059.52
–

–
–

–
–

–

–

–

–

–

–

–

–

–

–

–
–

–
–

–

–

–
–
–

–
–
–

–
–
2,962,442,073.05
–
–
–
1,151,042,575.80
–
–
–

–
–
255,928,059.52
–
–
–
174,815,165.99
–
–
–

Accumulated amount
for the year

Item
IX. Distributable profit

Accumulated
amount for the
corresponding
period of last year

4,113,484,648.85

430,743,225.51

    Less: Appropriation of statutory surplus reserve

–

–

      Appropriation for staff bonuses and
       benefit funds

–

–

      Appropriation for reserve funds

–

–

      Appropriation for company development funds

–

–

      Others

–

–

4,113,484,648.85

430,743,225.51

–

–

(800,000,000.00)

–

    Ordinary shares dividends converted to equity

–

–

   Others

–

–

3,313,484,648.85

430,743,225.51

X. Distributable profit attributable to investors
    Preference shares dividends payable
    Appropriation of discretionary surplus reserve
    Ordinary shares dividends payable

XI. Undistributed profit

– 14 –

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
STATEMENT OF CASH FLOWS
JANUARY TO JUNE 2026
Unit: RMB
Accumulated
amount for the
corresponding
period of last year

Accumulated
amount for the year

Item
I. Cash flow from operating activities:
Cash received from the sales of goods and the
rendering of services

514,910.54

500,000.00

–

–

1,083,985,528.22

356,901,376.13

1,084,500,438.76

357,401,376.13

627,108.13

5,950.95

Cash paid to and for employees

92,924,622.35

87,878,775.01

Payments of all types of taxes

703,149.03

330,437.57

853,212,884.91

440,882,839.45

Sub-total of cash outflows from operating activities

947,467,764.42

529,098,002.98

Net cash flow from operating activities

137,032,674.34

(171,696,626.85)

Cash received from investment recovery

3,473,782,030.50

4,082,996,149.00

Cash received from returns on investments

755,153,079.77

393,725,893.66

Net cash received from disposals of fixed assets,
intangible assets and other long-term assets

–

–

Net cash received from disposals of subsidiaries and
other operating units

–

–

Cash received relating to other investing activities

–

802.28

4,228,935,110.27

4,476,722,844.94

232,274.21

50,506.20

3,540,000,000.00

1,680,000,000.00

Net cash paid for acquisition of subsidiaries and other
operating units

–

371,636,801.95

Cash payments relating to other investing activities

–

–

Sub-total of cash outflows from investing activities

3,540,232,274.21

2,051,687,308.15

Net cash flow from investing activities

688,702,836.06

2,425,035,536.79

Refund of taxes and levies
Cash received relating to other operating activities
Sub-total of cash inflows from operating activities
Cash paid for goods purchased and services received

Cash payments relating to other operating activities

II. Cash flow from investing activities:

Sub-total of cash inflows from investing activities
Cash paid to acquire fixed assets, intangible assets
and other long-term assets
Cash paid for investments

– 15 –

Accumulated
amount for the
corresponding
period of last year

Accumulated
amount for the year

Item
III. Cash flow from financing activities:
Cash received from capital contribution

–

–

–

87,000,000.00

Cash received from issuance of bonds

1,500,000,000.00

–

Cash received relating to other financing activities

918,871,610.98

1,201,331,231.30

Sub-total of cash inflows from financing activities

2,418,871,610.98

1,288,331,231.30

Cash payments for debts settlement

1,511,866,667.00

2,000,000,000.00

Cash payments for distribution of dividends, profits,
or interest expenses

34,346,990.16

140,808,008.61

Including: Dividends and profits paid by
      subsidiaries to minority shareholders

–

–

Cash payments relating to other financing activities

985,255,737.49

588,224,433.50

Sub-total of cash outflows from financing activities

2,531,469,394.65

2,729,032,442.11

Net cash flow from financing activities

(112,597,783.67)

(1,440,701,210.81)

(70.44)

(28.63)

713,137,656.29

812,637,670.50

575,327,754.56

540,934,149.52

1,288,465,410.85

1,353,571,820.02

Including: Cash received by subsidiaries from
      investments of minority shareholders
Cash received from borrowings

IV. Effect of foreign exchange rate changes on cash and
   cash equivalents
V. Net increase in cash and cash equivalents
Add: Opening balance of cash and cash equivalents
VI. Closing balance of cash and cash equivalents

– 16 –

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不
負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告
全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。

（於香港註冊成立的有限公司）

（股份代號：3320）

公

告

有關於中國發行中期票據及公司債券的
華 潤 醫 藥 控 股 截 至 2026 年 6 月 30 日 止 六 個 月 的
未經審核財務業績
謹 此 提 述 (i) 日 期 為 2026 年 5 月 29 日 關 於（其 中 包 括）本 公 司 的 全 資 附 屬 公 司 華 潤
醫 藥 控 股 有 限 公 司（「華 潤 醫 藥 控 股」）建 議 於 中 國 發 行 中 期 票 據 的 公 告；(ii) 日
期 為 2026 年 7 月 22 日 關 於（其 中 包 括）華 潤 醫 藥 控 股 已 完 成 於 中 國 發 行 2026 年 第
一 期 中 期 票 據 的 公 告；(iii) 日 期 為 2026 年 7 月 29 日 關 於（其 中 包 括）華 潤 醫 藥 控 股
已 完 成 於 中 國 發 行 2026 年 第 二 期 中 期 票 據 的 公 告；及 (iv) 日 期 為 2026 年 4 月 16 日
關 於（其 中 包 括）華 潤 醫 藥 控 股 已 完 成 於 中 國 發 行 2026 年 第 一 期 公 司 債 券 的 公
告（「該 等 公 告」）。除 本 公 告 另 有 說 明 外，本 公 告 所 用 詞 彙 與 該 等 公 告 所 界 定 者
具 有 相 同 涵 義。
根 據 中 國 相 關 規 則 及 法 規 及 就 其 於 中 國 發 行 中 期 票 據 及 公 司 債 券 而 言，華 潤
醫藥控股已就中期票據於中國貨幣網和上海清算所網站以及就公司債券於上
海 證 券 交 易 所 網 站 刊 載 其 截 至 2026 年 6 月 30 日 止 六 個 月 的 未 經 審 核 財 務 報 表。

–1–

華 潤 醫 藥 控 股 截 至 2026 年 6 月 30 日 止 六 個 月 的 未 經 審 核 財 務 報 表（「華 潤 醫 藥 控
股 未 經 審 核 財 務 報 表」）隨 附 於 本 公 告 內，僅 供 本 公 司 股 東 參 考。華 潤 醫 藥 控
股 未 經 審 核 財 務 報 表 最 初 以 中 文 編 製，並 已 翻 譯 以 作 英 文 及 中 文 刊 載。如 中
英 文 版 本 有 任 何 歧 義，概 以 中 文 版 為 準。此 外，華 潤 醫 藥 控 股 未 經 審 核 財 務
報 表 乃 根 據 中 國 公 認 會 計 原 則 編 製，未 經 本 公 司 核 數 師 審 閱 或 審 核，且 可 能
須 於 審 核 過 程 中 作 出 調 整。有 關 財 務 資 料 僅 限 於 華 潤 醫 藥 控 股，並 不 能 全 面
反 映 本 集 團 的 營 運 或 財 務 狀 況。
股 東 及 潛 在 投 資 者 於 買 賣 本 公 司 證 券 時 務 請 謹 慎 行 事，且 不 應 完 全 依 賴 該 等 資 料。
承董事會命
華潤醫藥集團有限公司
主席
白曉松先生
中 國，2026 年 8 月 31 日

於 本 公 告 日 期，董 事 會 包 括 主 席 及 執 行 董 事 白 曉 松 先 生；執 行 董 事 程 杰 先 生
及 劉 長 安 先 生；非 執 行 董 事 郭 巍 女 士、孫 永 強 先 生、王 宇 航 先 生、張 靜 女 士 及
焦 瑞 芳 女 士；及 獨 立 非 執 行 董 事 招 敏 慧 女 士、傅 廷 美 先 生、張 克 堅 先 生 及 史
錄 文 先 生。

–2–

華潤醫藥控股有限公司
合併資產負債表
2026 年 6 月
項目

期末數

年初數

項目

流 動 資 產：

金 額 單 位：人 民 幣 元
期末數

年初數

44,692,759,737.02

40,737,794,364.47

–

–

應付票據及應付賬款

65,908,865,355.13

64,745,270,978.14

流 動 負 債：

貨幣資金

24,680,256,863.94

24,173,133,594.20

短期借款

交易性金融資產

10,879,098,404.39

12,069,041,094.95

交易性金融負債

–

–

應收票據

374,454,089.28

586,483,121.19

其 中：應 付 票 據

20,297,849,182.80

21,745,649,407.90

應收賬款

99,068,638,292.38

92,595,722,664.81

應付賬款

45,611,016,172.33

42,999,621,570.24

應收款項融資

13,525,522,072.38

13,178,431,543.53

預收款項

355,407,534.46

93,937,978.20

預付款項

3,961,276,642.20

4,016,056,359.42

合同負債

3,224,567,057.34

4,182,764,833.36

其他應收款

9,635,870,826.95

8,622,449,150.11

應付職工薪酬

3,475,568,745.16

4,211,743,649.25

其 中：應 收 利 息

132,725.08

836,001.52

其 中：應 付 工 資

861,876,546.30

1,080,675,958.90

應收股利

0.00

0.00

–

–

存貨

45,080,474,462.02

43,276,039,279.45

應交稅費

1,631,661,027.51

2,015,479,566.00

其 中：原 材 料

3,634,045,013.21

3,202,249,965.23

其 中：應 交 稅 金

1,503,567,571.30

1,868,335,230.98

庫 存 商 品（產 成 品）

37,257,851,681.00

35,292,622,462.01

其他應付款

24,635,830,504.12

21,431,783,225.55

合同資產

41,872,924.04

55,493,546.50

其 中：應 付 利 息

8,088,805.93

7,674,319.44

持有待售資產

35,325,622.46

37,996,383.69

應付股利

8,116,592,298.36

4,732,832,203.56

一年內到期的非流動資產

2,483,202,773.94

3,235,028,566.39

保險合同準備金

–

–

其他流動資產

2,147,064,651.73

2,301,374,310.71

持有待售負債

–

–

一年內到期的非流動負債

8,374,185,320.59

8,110,938,853.35

其他流動負債

491,284,448.09

640,430,558.82

152,790,129,729.43

146,170,144,007.14

衍生金融資產

流動資產合計

211,913,057,625.71

流動負債合計

204,147,249,614.95

非 流 動 資 產：
其他債權投資

應付福利費

非 流 動 負 債：
(0.00)

(0.00)

長期借款

6,461,295,929.71

11,149,853,384.60

債權投資

83,280,094.96

79,280,094.96

應付債券

16,724,264,218.64

10,196,868,303.42

長期應收款

707,155,910.31

831,459,823.02

長期應付款

404,335,926.29

408,549,258.29

其他權益工具投資

10,942,625.57

10,942,625.57

其 中：長 期 應 付 款

160,785,920.00

160,785,920.00

長期股權投資

6,159,357,322.02

6,041,161,311.87

專項應付款

243,550,006.29

247,763,338.29

投資性房地產

368,892,763.15

353,339,799.28

長期應付職工薪酬

733,554,214.92

744,513,538.04

其他非流動金融資產

828,439,946.03

833,242,321.57

△遞延收益

798,590,348.64

781,520,816.97

22,293,386,897.16

22,712,024,741.91

預計負債

1,362,459.98

1,321,000.65

11,523,424.85

9,711,113.40

遞延所得稅負債

1,795,841,755.54

1,892,214,582.04

使用權資產

1,157,390,021.26

1,279,364,857.34

租賃負債

723,869,951.72

730,025,422.66

在建工程

3,097,613,615.41

2,587,796,563.58

其他非流動負債

3,814,940.00

3,814,940.00

其 中：工 程 物 資

208,228.24

168,450.73

其 中：特 准 儲 備 基 金

生產性生物資產

24,382,688.45

20,585,150.19

非流動負債合計

27,646,929,745.43

25,908,681,246.67

–

–

負債合計

180,437,059,474.86

172,078,825,253.81

固定資產
其 中：固 定 資 產 清 理

油氣資產

–3–

項目

期末數

年初數

項目

期末數

年初數

無形資產

13,253,860,993.21

13,309,319,592.85 所 有 者 權 益（或 股 東 權 益）：

其 中：土 地 使 用 權

5,018,407,870.15

4,882,090,433.67

實 收 資 本（股 本）

21,007,000,000.00

21,007,000,000.00

開發支出

2,939,120,770.30

2,960,721,894.91

國家資本

商譽

24,354,410,933.42

24,342,133,911.47

集體資本

長期待攤費用

461,200,577.98

473,179,715.38

法人資本

遞延所得稅資產

2,512,484,138.50

2,347,164,484.40

其 中：國 有 法 人 資 本

其他非流動資產

4,284,042,317.57

3,974,805,304.11

集體法人資本

其 中：合 同 資 產

2,211,431.50

2,342,483.75

185,353,464.71

165,697,373.12

其他綜合收益

33,388,819.91

46,898,136.52

其 中：外 幣 報 表 折 算 差 額

18,171,619.40

25,606,055.86

盈餘公積

972,961,454.68

972,961,454.68

專項儲備

4,992,022.37

5,027,989.57

未分配利潤

19,188,969,577.01

18,176,543,251.84

歸屬於母公司所有者
權益合計

41,392,665,338.68

40,374,128,205.73

△少數股東權益

72,619,294,427.45

73,850,818,347.82

所有者權益合計

114,011,959,766.13

114,224,946,553.55

負債和所有者權益總計

294,449,019,241.00

286,303,771,807.36

個人資本
外商資本
資本公積
減：庫 存 股

非流動資產合計

資產總計

82,535,961,615.29

294,449,019,241.00

82,156,522,192.41

286,303,771,807.36

–4–

華潤醫藥控股有限公司
合併利潤表
2026 年 1–6 月
金 額 單 位：人 民 幣 元
項目

本年累計

上年同期累計

135,345,023,439.83

132,788,187,014.49

其 中： 主 營 業 務 收 入

134,436,416,385.13

131,819,175,565.31

其他業務收入

908,607,054.70

969,011,449.18

112,731,650,116.58

110,405,051,414.85

其 中： 主 營 業 務 成 本

112,340,862,015.89

109,852,909,737.49

其他業務成本

390,788,100.69

552,141,677.37

稅金及附加

600,880,475.65

579,908,148.25

銷售費用

10,145,719,012.94

9,998,189,637.77

管理費用

3,237,724,104.94

3,149,879,296.45

20,765,044.65

24,416,660.91

研發費用

1,112,513,313.85

970,848,372.56

財務費用

790,919,399.87

804,490,493.72

其 中： 利 息 費 用

849,077,013.00

957,146,131.17

利息收入

146,470,116.34

205,354,012.40

匯 兌 淨 損 失（淨 收 益 以「–」號 填 列）

40,951,803.53

8,605,216.38

其他收益

246,532,315.55

375,616,257.22

投 資 收 益（損 失 以「–」號 填 列）

170,541,178.03

82,373,762.10

146,236,168.09

127,376,865.49

–

–

16,460,592.44

61,246,808.99

資產減值損失

128,567,398.52

227,651,013.87

信用減值損失

641,013,734.75

624,663,311.88

資產處置收益

13,222,857.86

13,182,876.27

三、營 業 利 潤（虧 損 以「–」號 填 列）

6,402,792,826.60

6,559,925,029.73

98,750,504.65

113,180,345.42

–

–

–

14,833.18

55,156,861.42

64,875,650.61

–

–

一、營 業 收 入

二、營 業 成 本

其 中：業 務 招 待 費

其 中：對 聯 營 企 業 和 合 營 企 業 的 投 資 收 益
淨 敞 口 套 期 收 益（損 失 以「–」號 填 列）
加：公 允 價 值 變 動 收 益（損 失 以「–」號 填 列）

加：營 業 外 收 入
其 中：非 貨 幣 性 資 產 交 換 利 得
政府補助
減：營 業 外 支 出
其 中：非 貨 幣 性 資 產 交 換 損 失

–5–

項目

本年累計

四、利 潤 總 額（虧 損 總 額 以「–」號 填 列）

上年同期累計

6,446,386,469.83

6,608,229,724.55

1,270,860,231.83

1,365,709,737.55

5,175,526,237.99

5,242,519,986.99

歸屬於母公司所有者的淨利潤

1,815,408,773.85

1,760,234,549.32

*少 數 股 東 損 益

3,294,742,464.14

3,449,760,437.67

65,375,000.00

32,525,000.00

(83,813,071.95)

(4,748,111.08)

(50,505,211.54)

1,779,097.42

2,704.45

–

(50,507,915.99)

1,721,273.79

其他權益工具投資公允價值變動

(0.00)

57,823.63

（二）將 重 分 類 進 損 益 的 其 他 綜 合 收 益

(33,307,860.40)

(6,527,208.51)

(50,351.81)

110,918.16

264.35

(12,986.68)

金融資產重分類計入其他綜合收益的
金額

–

–

其他債權投資信用減值準備

–

–

固定資產重估

–

–

現金流量套期儲備

–

–

(33,255,068.49)

(6,625,139.98)

(2,704.45)

0.00

5,091,713,166.05

5,237,771,875.91

–

–

基本每股收益

–

–

稀釋每股收益

–

–

18,174,155,591.48

14,950,877,474.62

會計政策變更

–

(0.00)

盈餘公積補虧

–

–

其他調整因素

–

0.00

減：所 得 稅 費 用
五、淨 利 潤（淨 虧 損 以「–」號 填 列）
其 中：同 一 控 制 下 企 業 合 拼 中 被 合 拼 方
合拼前淨利潤

永續資本工具持有人應佔利潤
六、其 他 綜 合 收 益 的 稅 後 淨 額
（一）不 能 重 分 類 進 損 益 的 其 他 綜 合 收 益
重新計量設定受益計劃變動額
權益法下不能轉損益的其他綜合收益

權益法下可轉損益的其他綜合收益
其他債權投資公允價值變動

外幣財務報表折算差額
其他
七、綜 合 收 益 總 額
八、每 股 收 益：

加：年 初 未 分 配 利 潤

–6–

項目

本年累計

九、可 供 分 配 的 利 潤

上年同期累計

19,989,564,365.34

16,711,112,023.95

0.00

(0.01)

提取職工工資獎勵及福利基金

–

–

提取儲備基金

–

–

提取企業發展基金

–

–

其他

–

–

19,989,564,365.34

16,711,112,023.94

–

–

(800,000,000.00)

0.00

–

–

(594,788.33)

0.00

19,188,969,577.01

16,711,112,023.94

減：提 取 法 定 盈 餘 公 積

十、可 供 投 資 者 分 配 的 利 潤
應付優先股股利
提取任意盈餘公積
應付普通股股利
轉作股本的普通股股利
其他
十 一、未 分 配 利 潤

–7–

華潤醫藥控股有限公司
合併現金流量表
2026 年 1–6 月
金 額 單 位：人 民 幣 元
項目

本年累計

上年同期累計

一、經 營 活 動 產 生 的 現 金 流 量：
銷 售 商 品、提 供 勞 務 收 到 的 現 金

138,716,345,824.69

135,507,491,291.93

53,836,762.11

76,320,240.24

收到其他與經營活動有關的現金

7,217,432,178.84

7,347,921,499.59

經營活動現金流入小計

145,987,614,765.64

142,931,733,031.77

購 買 商 品、接 收 勞 務 支 付 的 現 金

115,423,162,404.46

113,538,539,355.47

支付給職工以及為職工支付的現金

8,485,704,094.36

7,848,085,899.47

支付的各項稅費

5,554,564,618.32

5,476,681,095.13

支付其他與經營活動有關的現金

15,075,392,607.24

14,493,601,581.10

經營活動現金流出小計

144,538,823,724.38

141,356,907,931.16

經營活動產生的現金流量淨額

1,448,791,041.26

1,574,825,100.61

26,769,699,100.39

17,053,655,729.22

取得投資收益收到的現金

350,218,602.95

276,697,356.21

處 置 固 定 資 產、無 形 資 產 和
其他長期資產所收回的現金淨額

318,456,176.62

46,060,223.24

處置子公司及其他營業單位收回的
現金淨額

–

11,911,840.85

收到其他與投資活動有關的現金

22,366,509.48

240,751,726.94

投資活動現金流入小計

27,460,740,389.44

17,629,076,876.46

購 建 固 定 資 產、無 形 資 產 和
其他長期資產所支付的現金

1,632,714,643.05

1,506,537,871.93

投資支付的現金

25,972,990,044.25

16,396,527,175.68

取得子公司及其他營業單位支付的
現金淨額

39,993,482.41

5,109,142,594.38

支付其他與投資活動有關的現金

343,402,560.36

(479,208.49)

投資活動現金流出小計

27,989,100,730.07

23,011,728,433.50

投資活動產生的現金流量淨額

(528,360,340.63)

(5,382,651,557.04)

收到的稅費返還

二、投 資 活 動 產 生 的 現 金 流 量：
收回投資收到的現金

–8–

項目

本年累計

上年同期累計

三、籌 資 活 動 產 生 的 現 金 流 量：
吸收投資收到的現金

19,492,000.00

114,593,600.00

取得借款所收到的現金

32,342,296,506.12

40,604,790,301.78

發行債券收到的現金

7,699,820,000.00

5,000,000,000.00

收到其他與籌資活動有關的現金

2,393,370,709.76

3,303,425,997.44

籌資活動現金流入小計

42,454,979,215.88

49,022,809,899.22

償還債務所支付的現金

38,146,011,708.03

38,956,630,236.10

分 配 股 利、利 潤 或 償 付 利 息 所 支 付
的現金

2,694,062,264.11

2,458,372,059.72

其 中：子 公 司 支 付 給 少 數 股 東 的
股 利、利 潤

117,623,400.30

3,471,170.03

支付其他與籌資活動有關的現金

2,727,310,927.13

2,868,039,263.48

籌資活動現金流出小計

43,567,384,899.27

44,283,041,559.30

籌資活動產生的現金流量淨額

(1,112,405,683.39)

4,739,768,339.93

四、匯 率 變 動 對 現 金 及 現 金 等 價 物 的 影 響

(29,659,022.05)

1,460,601.10

五、現 金 及 現 金 等 價 物 淨 增 加 額

(221,634,004.81)

933,402,484.59

15,765,241,201.49

16,323,306,375.52

15,543,607,196.68

17,256,708,860.11

其 中：子 公 司 吸 收 少 數 股 東 投 資
收到的現金

加：期 初 現 金 及 現 金 等 價 物 餘 額
六、期 末 現 金 及 現 金 等 價 物 餘 額

–9–

華潤醫藥控股有限公司
資產負債表
2026 年 6 月
金 額 單 位：人 民 幣 元
項目

期末數

年初數

項目

流 動 資 產：

期末數

年初數

1,006,471,111.11

1,501,386,666.66

流 動 負 債：

貨幣資金

1,388,465,410.85

605,327,754.56

短期借款

交易性金融資產

1,557,938,847.27

1,605,145,283.04

交易性金融負債

–

–

衍生金融資產

–

–

應付票據及應付賬款

–

–

應收票據

–

–

其 中：應 付 票 據

–

–

應收賬款

–

–

應付賬款

–

–

應收款項融資

–

–

預收款項

–

–

2,233,076.30

190,584.60

合同負債

–

–

14,032,381,079.08

12,231,194,371.37

57,286,224.80

65,267,041.33

其 中：應 收 利 息

–

–

–

–

應收股利

8,867,748,449.32

6,572,748,449.32

–

–

存貨

–

–

應交稅費

7,082,927.12

7,768,096.09

其 中：原 材 料

–

–

其 中：應 交 稅 金

7,082,927.12

7,768,096.09

–

–

其他應付款

1,579,112,939.90

1,151,408,704.22

合同資產

–

–

其 中：應 付 利 息

–

–

持有待售資產

–

–

應付股利

800,000,000.00

–

一年內到期的非流動資產

–

–

保險合同準備金

–

–

2,413,301.74

2,379,335.64

持有待售負債

–

–

1,312,034,422.37

2,312,950,189.86

–

–

3,961,987,625.30

5,038,780,698.16

預付款項
其他應收款

庫 存 商 品（產 成 品）

其他流動資產

應付職工薪酬
其 中：應 付 工 資
應付福利費

一年內到期的非流動負債
其他流動負債
流動資產合計

16,983,431,715.24

流動負債合計

14,444,237,329.21

非 流 動 資 產：

非 流 動 負 債：

其他債權投資

–

–

長期借款

205,125,187.04

222,082,502.61

債權投資

–

–

應付債券

3,726,169,611.11

2,200,000,000.00

長期應收款

–

–

長期應付款

–

–

其他權益工具投資

–

–

其 中：長 期 應 付 款

–

–

長期股權投資

16,743,443,766.56

16,698,998,641.73

專項應付款

–

–

投資性房地產

–

–

長期應付職工薪酬

221,450,000.00

232,660,000.00

其他非流動金融資產

–

–

△遞延收益

–

–

2,817,777.16

2,545,046.50

預計負債

–

–

–

–

遞延所得稅負債

–

–

23,805,956.33

27,206,807.21

17,733,789.53

21,133,725.58

在建工程

–

260,030.96

–

–

其 中：工 程 物 資

–

–

其 中：特 准 儲 備 基 金

生產性生物資產

–

–

非流動負債合計

4,170,478,587.68

2,675,876,228.19

油氣資產

–

–

負債合計

8,132,466,212.98

7,714,656,926.35

固定資產
其 中：固 定 資 產 清 理
使用權資產

租賃負債
其他非流動負債

– 10 –

項目

期末數

年初數

項目

期末數

年初數

21,007,000,000.00

21,007,000,000.00

資本公積

13,253,773.51

13,253,773.51

減：庫 存 股

–

–

74,610,416.58

74,610,416.58

–

–

盈餘公積

1,213,171,274.84

1,213,171,274.84

專項儲備

–

–

未分配利潤

3,313,484,648.85

1,151,042,575.80

歸屬於母公司所有者
權益合計

25,621,520,113.78

23,459,078,040.73

△少數股東權益

–

–

所有者權益合計

25,621,520,113.78

23,459,078,040.73

負債和所有者權益總計

33,753,986,326.76

31,173,734,967.08

無形資產

–

– 所 有 者 權 益（或 股 東 權 益）：

其 中：土 地 使 用 權

–

–

實 收 資 本（股 本）

開發支出

–

–

國家資本

商譽

–

–

集體資本

長期待攤費用

–

–

法人資本

遞延所得稅資產

487,111.47

487,111.47

其 中：國 有 法 人 資 本

其他非流動資產

–

–

集體法人資本

其 中：合 同 資 產

–

–

個人資本
外商資本

其他綜合收益
其 中：外 幣 報 表 折 算 差 額
非流動資產合計

資產總計

16,770,554,611.52

33,753,986,326.76

16,729,497,637.87

31,173,734,967.08

– 11 –

華潤醫藥控股有限公司
利潤表
2026 年 1–6 月
金 額 單 位：人 民 幣 元
項目

本年累計

一、營 業 收 入

上年同期累計

471,698.11

471,698.11

其 中： 主 營 業 務 收 入

–

–

其他業務收入

471,698.11

471,698.11

–

–

其 中： 主 營 業 務 成 本

–

–

其他業務成本

–

–

703,149.03

291,648.33

銷售費用

–

–

管理費用

88,569,983.21

62,850,288.09

25,032.20

53,850.30

研發費用

–

–

財務費用

60,062,898.49

76,518,876.58

其 中： 利 息 費 用

60,751,434.10

89,379,278.85

利息收入

722,620.46

13,964,556.56

(1,803,348.74)

(730,955.76)

–

166,065.61

3,094,598,204.60

391,330,397.95

44,445,124.83

67,449,931.01

–

–

16,575,594.73

17,559,802.84

資產減值損失

–

–

信用減值損失

–

32,069,477.09

資產處置收益

–

–

2,962,309,466.71

237,797,674.42

675,606.34

20,411,740.24

–

–

–

–

543,000.00

2,950,000.00

–

–

二、營 業 成 本

稅金及附加

其 中： 業 務 招 待 費

匯 兌 淨 損 失（淨 收 益 以「–」號 填 列）
其他收益
投 資 收 益（損 失 以「–」號 填 列）
其 中：對 聯 營 企 業 和 合 營 企 業 的 投 資 收 益
淨 敞 口 套 期 收 益（損 失 以「–」號 填 列）
加：公 允 價 值 變 動 收 益（損 失 以「–」號 填 列）

三、營 業 利 潤（虧 損 以「–」號 填 列）
加：營 業 外 收 入
其 中：非 貨 幣 性 資 產 交 換 利 得
政府補助
減：營 業 外 支 出
其 中：非 貨 幣 性 資 產 交 換 損 失

– 12 –

項目

本年累計

四、利 潤 總 額（虧 損 總 額 以「–」號 填 列）

上年同期累計

2,962,442,073.05

255,259,414.66

–

(668,644.86)

2,962,442,073.05

255,928,059.52

2,962,442,073.05

255,928,059.52

*少 數 股 東 損 益

–

–

永續資本工具持有人應佔利潤

–

–

–

–

（一）不 能 重 分 類 進 損 益 的 其 他 綜 合 收 益

–

–

重新計量設定受益計劃變動額

–

–

權益法下不能轉損益的其他綜合收益

–

–

其他權益工具投資公允價值變動

–

–

（二）將 重 分 類 進 損 益 的 其 他 綜 合 收 益

–

–

權益法下可轉損益的其他綜合收益

–

–

其他債權投資公允價值變動

–

–

金融資產重分類計入其他綜合收益
的金額

–

–

其他債權投資信用減值準備

–

–

固定資產重估

–

–

現金流量套期儲備

–

–

外幣財務報表折算差額

–

–

其他

–

–

2,962,442,073.05

255,928,059.52

–

–

基本每股收益

–

–

稀釋每股收益

–

–

1,151,042,575.80

174,815,165.99

會計政策變更

–

–

盈餘公積補虧

–

–

其他調整因素

–

–

減：所 得 稅 費 用
五、淨 利 潤（淨 虧 損 以「–」號 填 列）
其 中：同 一 控 制 下 企 業 合 拼 中 被 合 拼 方
合拼前淨利潤
歸屬於母公司所有者的淨利潤

六、其 他 綜 合 收 益 的 稅 後 淨 額

七、綜 合 收 益 總 額
八、每 股 收 益：

加：年 初 未 分 配 利 潤

– 13 –

項目

本年累計

九、可 供 分 配 的 利 潤

上年同期累計

4,113,484,648.85

430,743,225.51

–

–

提取職工工資獎勵及福利基金

–

–

提取儲備基金

–

–

提取企業發展基金

–

–

其他

–

–

4,113,484,648.85

430,743,225.51

–

–

(800,000,000.00)

–

轉作股本的普通股股利

–

–

其他

–

–

3,313,484,648.85

430,743,225.51

減：提 取 法 定 盈 餘 公 積

十、可 供 投 資 者 分 配 的 利 潤
應付優先股股利
提取任意盈餘公積
應付普通股股利

十 一、未 分 配 利 潤

– 14 –

華潤醫藥控股有限公司
現金流量表
2026 年 1–6 月
金 額 單 位：人 民 幣 元
項目

本年累計

上年同期累計

一、經 營 活 動 產 生 的 現 金 流 量：
銷 售 商 品、提 供 勞 務 收 到 的 現 金

514,910.54

500,000.00

–

–

收到其他與經營活動有關的現金

1,083,985,528.22

356,901,376.13

經營活動現金流入小計

1,084,500,438.76

357,401,376.13

購 買 商 品、接 收 勞 務 支 付 的 現 金

627,108.13

5,950.95

支付給職工以及為職工支付的現金

92,924,622.35

87,878,775.01

703,149.03

330,437.57

支付其他與經營活動有關的現金

853,212,884.91

440,882,839.45

經營活動現金流出小計

947,467,764.42

529,098,002.98

經營活動產生的現金流量淨額

137,032,674.34

(171,696,626.85)

收回投資收到的現金

3,473,782,030.50

4,082,996,149.00

取得投資收益收到的現金

755,153,079.77

393,725,893.66

處 置 固 定 資 產、無 形 資 產 和
其他長期資產所收回的現金淨額

–

–

處置子公司及其他營業單位收回的
現金淨額

–

–

收到其他與投資活動有關的現金

–

802.28

投資活動現金流入小計

4,228,935,110.27

4,476,722,844.94

232,274.21

50,506.20

3,540,000,000.00

1,680,000,000.00

取得子公司及其他營業單位支付的
現金淨額

–

371,636,801.95

支付其他與投資活動有關的現金

–

–

投資活動現金流出小計

3,540,232,274.21

2,051,687,308.15

投資活動產生的現金流量淨額

688,702,836.06

2,425,035,536.79

收到的稅費返還

支付的各項稅費

二、投 資 活 動 產 生 的 現 金 流 量：

購 建 固 定 資 產、無 形 資 產 和
其他長期資產所支付的現金
投資支付的現金

– 15 –

項目

本年累計

上年同期累計

三、籌 資 活 動 產 生 的 現 金 流 量：
吸收投資收到的現金

–

–

–

87,000,000.00

發行債券收到的現金

1,500,000,000.00

–

收到其他與籌資活動有關的現金

918,871,610.98

1,201,331,231.30

籌資活動現金流入小計

2,418,871,610.98

1,288,331,231.30

1,511,866,667.00

2,000,000,000.00

分 配 股 利、利 潤 或 償 付 利 息 所 支 付
的現金

34,346,990.16

140,808,008.61

其 中：子 公 司 支 付 給 少 數 股 東 的
股 利、利 潤

–

–

支付其他與籌資活動有關的現金

985,255,737.49

588,224,433.50

籌資活動現金流出小計

2,531,469,394.65

2,729,032,442.11

籌資活動產生的現金流量淨額

(112,597,783.67)

(1,440,701,210.81)

(70.44)

(28.63)

713,137,656.29

812,637,670.50

575,327,754.56

540,934,149.52

1,288,465,410.85

1,353,571,820.02

其 中：子 公 司 吸 收 少 數 股 東 投 資
收到的現金
取得借款所收到的現金

償還債務所支付的現金

四、匯 率 變 動 對 現 金 及 現 金 等 價 物 的 影 響
五、現 金 及 現 金 等 價 物 淨 增 加 額
加：期 初 現 金 及 現 金 等 價 物 餘 額
六、期 末 現 金 及 現 金 等 價 物 餘 額

– 16 –